

Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones

Clark W. Distelhorst

PII: S0167-4889(18)30210-6
DOI: doi:10.1016/j.bbamcr.2018.07.020
Reference: BBAMCR 18328

To appear in: *BBA - Molecular Cell Research*

Received date: 13 March 2018
Revised date: 18 July 2018
Accepted date: 19 July 2018

Please cite this article as: Clark W. Distelhorst , Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones. Bbamcr (2018), doi:10.1016/j.bbamcr.2018.07.020

Targeting Bcl-2-IP_3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones

Clark W. Distelhorst

Case Western University School of Medicine, Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio 44106

Corresponding Author:

Clark W. Distelhorst, MD

Department of Medicine

Case Western Reserve University School of Medicine

10900 Euclid Avenue

Cleveland, Ohio 44106

E-mail: cwd@case.edu

Phone: 216-368-4546

Key Words:

Bcl-2, inositol 1,4,5-trisphosphate receptor (IP_3R), calcium (Ca^{2+}), endoplasmic reticulum, apoptosis, adrenal corticosteroid hormones, dexamethasone, prednisone